Intelligence Platform

Patents

Browse 379 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12416006

Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use ther

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12404508

Ketohexokinase (KHK) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12397013

Extrahepatic delivery

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12385043

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12385044

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12378553

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12364762

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12350338

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12343398

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12338439

Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and k

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12331297

Coagulation factor V (F5) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12290573

Modified RNAi agents

Alnylam Pharmaceuticals, Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12239709

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12241064

REVERSIR™ compounds

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227744

Compositions and methods for inhibiting expression of transthyretin

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221607

Multi-targeted single entity conjugates

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173289

Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173288

Oligonucleotide-ligand conjugates and process for their preparation

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12168767

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091666

Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12071619

SERPINA1 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12059468

Carbohydrate conjugates as delivery agents for oligonucleotides

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049630

Factor XII (F12) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049628

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventin

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted